In this study we investigated the effects of the novel myeloperoxidase (MPO) inhibitor AZM198 on obesity, liver damage and cardiac function in an obese and hypertensive mouse model, provoked by a high fat diet (HFD) combined with angiotensin II (AngII) infusion (HFD/AngII model). Here, MPO is linked to obesity due to melanocortin 4 receptor deficiency.